Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.
2.

Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients.

Barra S, Duehmke R, Providência R, Narayanan K, Reitan C, Roubicek T, Polasek R, Chow A, Defaye P, Fauchier L, Piot O, Deharo JC, Sadoul N, Klug D, Garcia R, Dockrill S, Virdee M, Pettit S, Agarwal S, Borgquist R, Marijon E, Boveda S.

Eur Heart J. 2019 Jul 1;40(26):2121-2127. doi: 10.1093/eurheartj/ehz238.

PMID:
31046090
3.

Sudden-onset severe presyncope in a 67-year-old man.

Sanders KH, Martin CA, Virdee M.

Heart. 2019 Apr;105(8):657-659. doi: 10.1136/heartjnl-2018-314118. Epub 2018 Dec 4.

PMID:
30514728
4.

Ablation of Complex Fractionated Electrograms Improves Outcome in Persistent Atrial Fibrillation of Over 2 Year's Duration.

Martin CA, Curtain JP, Gajendragadkar PR, Begley DA, Fynn SP, Grace AA, Heck PM, Virdee MS, Agarwal S.

J Atr Fibrillation. 2018 Feb 28;10(5):1607. doi: 10.4022/jafib.1607. eCollection 2018 Feb.

5.

Device complications with addition of defibrillation to cardiac resynchronisation therapy for primary prevention.

Barra S, Providência R, Boveda S, Duehmke R, Narayanan K, Chow AW, Piot O, Klug D, Defaye P, Gras D, Deharo JC, Milliez P, Da Costa A, Mondoly P, Gonzalez-Panizo J, Leclercq C, Heck P, Virdee M, Sadoul N, Le Heuzey JY, Marijon E.

Heart. 2018 Sep;104(18):1529-1535. doi: 10.1136/heartjnl-2017-312546. Epub 2018 Mar 14.

PMID:
29540431
6.

Do women benefit equally as men from the primary prevention implantable cardioverter-defibrillator?

Barra S, Providência R, Boveda S, Narayanan K, Virdee M, Marijon E, Agarwal S.

Europace. 2018 Jun 1;20(6):897-901. doi: 10.1093/europace/eux203.

PMID:
29016772
7.

Improved outcome and cost effectiveness in ablation of persistent atrial fibrillation under general anaesthetic.

Martin CA, Curtain JP, Gajendragadkar PR, Begley DA, Fynn SP, Grace AA, Heck PM, Salaunkey K, Virdee MS, Agarwal S.

Europace. 2018 Jun 1;20(6):935-942. doi: 10.1093/europace/eux057.

PMID:
28444228
8.

Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate.

Barra S, Boveda S, Providência R, Sadoul N, Duehmke R, Reitan C, Borgquist R, Narayanan K, Hidden-Lucet F, Klug D, Defaye P, Gras D, Anselme F, Leclercq C, Hermida JS, Deharo JC, Looi KL, Chow AW, Virdee M, Fynn S, Le Heuzey JY, Marijon E, Agarwal S; French-UK-Sweden CRT Network.

J Am Coll Cardiol. 2017 Apr 4;69(13):1669-1678. doi: 10.1016/j.jacc.2017.01.042.

9.

Optimizing the use of oral anticoagulant therapy for atrial fibrilation in primary care: a pharmacist-led intervention.

Virdee MS, Stewart D.

Int J Clin Pharm. 2017 Feb;39(1):173-180. doi: 10.1007/s11096-016-0419-x. Epub 2017 Jan 3.

PMID:
28050712
10.

Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis.

Barra S, Duehmke R, Providencia R, Marijon E, Boveda S, Virdee M, Heck P, Fynn S, Begley D, Grace A, Agarwal S.

Europace. 2018 Jan 1;20(1):89-96. doi: 10.1093/europace/euw321.

PMID:
28031276
11.
12.

Implantable cardioverter-defibrillator elective generator replacement: a procedure for all?

Barra S, Goonewardene M, Heck P, Begley D, Virdee M, Fynn S, Grace A, Agarwal S.

J Interv Card Electrophysiol. 2016 Mar;45(2):209-18. doi: 10.1007/s10840-015-0087-0. Epub 2016 Jan 12.

PMID:
26755207
13.

Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy.

Barra S, Looi KL, Gajendragadkar PR, Khan FZ, Virdee M, Agarwal S.

Europace. 2016 Aug;18(8):1187-93. doi: 10.1093/europace/euv352. Epub 2015 Nov 12.

PMID:
26566940
14.

Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis.

Barra S, Providência R, Tang A, Heck P, Virdee M, Agarwal S.

J Am Heart Assoc. 2015 Nov 6;4(11). pii: e002539. doi: 10.1161/JAHA.115.002539. Review.

15.

TNF receptor superfamily member 13b (TNFRSF13B) hemizygosity reveals transmembrane activator and CAML interactor haploinsufficiency at later stages of B-cell development.

Romberg N, Virdee M, Chamberlain N, Oe T, Schickel JN, Perkins T, Cantaert T, Rachid R, Rosengren S, Palazzo R, Geha R, Cunningham-Rundles C, Meffre E.

J Allergy Clin Immunol. 2015 Nov;136(5):1315-25. doi: 10.1016/j.jaci.2015.05.012. Epub 2015 Jun 19.

16.
17.

Cardioverter-defibrillator implantation and generator replacement in the octogenarian.

Goonewardene M, Barra S, Heck P, Begley D, Fynn S, Virdee M, Grace A, Agarwal S.

Europace. 2015 Mar;17(3):409-16. doi: 10.1093/europace/euu248. Epub 2014 Oct 23.

PMID:
25341742
18.

Development of a multiparametric score to predict left ventricular remodelling and prognosis after cardiac resynchronization therapy.

Kydd AC, Khan FZ, Ring L, Pugh PJ, Virdee MS, Dutka DP.

Eur J Heart Fail. 2014 Nov;16(11):1206-13. doi: 10.1002/ejhf.167. Epub 2014 Oct 10.

19.
20.

Cardiac resynchronisation therapy: pacemaker versus internal cardioverter-defibrillator in patients with impaired left ventricular function.

Looi KL, Gajendragadkar PR, Khan FZ, Elsik M, Begley DA, Fynn SP, Grace AA, Heck PM, Virdee M, Agarwal S.

Heart. 2014 May;100(10):794-9. doi: 10.1136/heartjnl-2014-305537. Epub 2014 Apr 1.

PMID:
24691411
21.

Utility of speckle tracking echocardiography to characterize dysfunctional myocardium in patients with ischemic cardiomyopathy referred for cardiac resynchronization therapy.

Kydd AC, Khan F, Gopalan D, Ring L, Rana BS, Virdee MS, Dutka DP.

Echocardiography. 2014 Jul;31(6):736-43. doi: 10.1111/echo.12458. Epub 2013 Dec 5.

PMID:
24303794
22.

CVID-associated TACI mutations affect autoreactive B cell selection and activation.

Romberg N, Chamberlain N, Saadoun D, Gentile M, Kinnunen T, Ng YS, Virdee M, Menard L, Cantaert T, Morbach H, Rachid R, Martinez-Pomar N, Matamoros N, Geha R, Grimbacher B, Cerutti A, Cunningham-Rundles C, Meffre E.

J Clin Invest. 2013 Oct;123(10):4283-93. doi: 10.1172/JCI69854. Epub 2013 Sep 24.

23.

Conscious sedation and analgesia use in cardiac device implantation.

Looi KL, Lee AS, Cole K, Agarwal S, Heck PM, Begley DA, Grace AA, Virdee M, Fynn SP.

Int J Cardiol. 2013 Sep 20;168(1):561-3. doi: 10.1016/j.ijcard.2013.01.167. Epub 2013 Feb 27. No abstract available.

PMID:
23452883
24.

Radial strain delay based on segmental timing and strain amplitude predicts left ventricular reverse remodeling and survival after cardiac resynchronization therapy.

Kydd AC, Khan FZ, O'Halloran D, Pugh PJ, Virdee MS, Dutka DP.

Circ Cardiovasc Imaging. 2013 Mar 1;6(2):177-84. doi: 10.1161/CIRCIMAGING.112.000191. Epub 2013 Jan 30.

PMID:
23363579
25.

Long-term outcomes (>2 years) of atrial fibrillation ablation using a multi-electrode ablation catheter in patients with paroxysmal atrial fibrillation.

Looi KL, Gajendragadkar P, Taha T, Elsik M, Scully E, Heck P, Fynn S, Virdee M, Begley D.

J Interv Card Electrophysiol. 2013 Jan;36(1):61-9; discussion 69. doi: 10.1007/s10840-012-9744-8. Epub 2012 Oct 25.

PMID:
23097007
26.

Supraventricular arrhythmias late after orthotopic cardiac transplantation: electrocardiographic and electrophysiological characterization and radiofrequency ablation.

Elsik M, Teh A, Ling LH, Virdee M, Parameshwar J, Fynn SP, Kistler PM.

Europace. 2012 Oct;14(10):1498-505. Epub 2012 Apr 20.

PMID:
22523376
27.

Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial.

Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O'Halloran D, Elsik M, Read PA, Begley D, Fynn SP, Dutka DP.

J Am Coll Cardiol. 2012 Apr 24;59(17):1509-18. doi: 10.1016/j.jacc.2011.12.030. Epub 2012 Mar 7.

28.

Oral amiodarone provoking inferior ST elevation and unmasking Brugada-like electrocardiogram feature.

Lee CW, Jassam Y, Braganza D, Virdee M.

Europace. 2012 Jul;14(7):1065-6. doi: 10.1093/europace/eur400. Epub 2011 Dec 19.

PMID:
22186778
29.

Cardiac resynchronization therapy optimization using noninvasive cardiac output measurement.

Khan FZ, Virdee MS, Hutchinson J, Smith B, Pugh PJ, Read PA, Fynn SP, Dutka DP.

Pacing Clin Electrophysiol. 2011 Nov;34(11):1527-36. doi: 10.1111/j.1540-8159.2011.03172.x.

PMID:
21797899
30.

Impact of VV optimization in relation to left ventricular lead position: an acute haemodynamic study.

Khan FZ, Virdee MS, Read PA, Pugh PJ, Begley D, Fynn SP, Dutka DP.

Europace. 2011 Jun;13(6):845-52. doi: 10.1093/europace/eur037. Epub 2011 Mar 21.

31.

The impact of the right ventricular lead position on response to cardiac resynchronization therapy.

Khan FZ, Salahshouri P, Duehmke R, Read PA, Pugh PJ, Elsik M, Begley D, Fynn SP, Dutka DP, Virdee MS.

Pacing Clin Electrophysiol. 2011 Apr;34(4):467-74. doi: 10.1111/j.1540-8159.2010.02995.x. Epub 2011 Jan 5.

PMID:
21208234
32.

Effect of low-amplitude two-dimensional radial strain at left ventricular pacing sites on response to cardiac resynchronization therapy.

Khan FZ, Virdee MS, Read PA, Pugh PJ, O'Halloran D, Fahey M, Elsik M, Begley D, Fynn SP, Dutka DP.

J Am Soc Echocardiogr. 2010 Nov;23(11):1168-76. doi: 10.1016/j.echo.2010.08.023.

PMID:
20888187
33.

Non-invasive cardiac output measurements based on bioreactance for optimization of atrio- and interventricular delays.

Khan FZ, Virdee MS, Pugh PJ, Read PA, Fynn SP, Dutka DP.

Europace. 2009 Dec;11(12):1666-74. doi: 10.1093/europace/eup358. Epub 2009 Nov 11.

PMID:
19910316
34.

Characterization of the suitability of coronary venous anatomy for targeting left ventricular lead placement in patients undergoing cardiac resynchronization therapy.

Khan FZ, Virdee MS, Gopalan D, Rudd J, Watson T, Fynn SP, Dutka DP.

Europace. 2009 Nov;11(11):1491-5. doi: 10.1093/europace/eup292.

PMID:
19880411
35.

Left ventricular lead placement in cardiac resynchronization therapy: where and how?

Khan FZ, Virdee MS, Fynn SP, Dutka DP.

Europace. 2009 May;11(5):554-61. doi: 10.1093/europace/eup076. Epub 2009 Apr 16. Review.

PMID:
19372115
36.

WolffParkinsonWhite syndrome and persistent azygous drainage of the inferior vena cava.

Virdee MS, Cooklin M, Gill JS.

BMJ Case Rep. 2009;2009:bcr2006101022. doi: 10.1136/bcr.2006.101022. Epub 2009 Feb 18. No abstract available.

37.

Wolff Parkinson White syndrome and persistent azygous drainage of the inferior vena cava.

Virdee MS, Cooklin M, Gill JS.

Heart. 2007 Oct;93(10):1166. No abstract available.

38.

Right ventricular septal pacing.

Leong FT, Goldsmith KA, Fynn SP, Virdee MS.

Pacing Clin Electrophysiol. 2007 Jul;30(7):934. No abstract available.

PMID:
17584281
39.
40.

Dual chamber pacing in hypertrophic cardiomyopathy: long-term effects on diastolic function.

Betocchi S, Elliott PM, Briguori C, Virdee M, Losi MA, Matsumura Y, Miranda M, McKenna WJ, Chiariello M.

Pacing Clin Electrophysiol. 2002 Oct;25(10):1433-40.

PMID:
12418740
41.
42.

Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes.

Sharma S, Elliott PM, Whyte G, Mahon N, Virdee MS, Mist B, McKenna WJ.

J Am Coll Cardiol. 2000 Sep;36(3):864-70.

43.

Ticlopidine and renal function.

Virdee M, Collinson J, Stables RH.

Lancet. 1996 Oct 12;348(9033):1031-2. No abstract available.

PMID:
8855878
44.

Blood pressure recording during carotid endarterectomy.

Phillips AJ, Virdee M.

Anaesthesia. 1991 Aug;46(8):697. No abstract available.

45.

Severe muscle spasm during surgery.

Mostafa SM, Virdee M.

Anaesthesia. 1985 Oct;40(10):1020. No abstract available.

Supplemental Content

Loading ...
Support Center